Bristol Myers Squibb Company claimed an immunotherapy first on 7 October when it reported top-line results from the Phase III CheckMate-816 clinical trial, as the first company to show that a checkpoint inhibitor-based combination therapy in the neoadjuvant setting was superior to chemotherapy in a Phase III study of resectable non-small cell lung cancer.
Bristol Claims A First With Opdivo In Neoadjuvant NSCLC
Co-Primary Endpoint Data May Support Early Approval
More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.
More from Immuno-oncology
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
More from Anticancer
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.